P2, N=976, Recruiting, MedSIR | Trial completion date: Dec 2028 --> Jun 2028 | Trial primary completion date: Dec 2028 --> Jun 2028

P=N/A, N=475, Recruiting, Memorial Sloan Kettering Cancer Center | Trial completion date: Feb 2026 --> Feb 2027 | Trial primary completion date: Feb 2026 --> Feb 2027

P2, N=95, Recruiting, Andrea DeCensi | N=70 --> 95

P=N/A, N=60, Not yet recruiting, Cairo University

Analysis of the correlation of 16 oppositely regulated genes with clinical data of breast cancer patients validated ST8SIA6 as the main candidate associated with adaptive stress tolerance. Overall, our findings indicate that the capacity to integrate metabolic and redox stress determines tumor cell type-specific responses to combined endocrine and oxysterol-induced stress in breast cancer.

Using mouse models of ER+BC (FVB/N mice, TC11 tumor model), we show reduced growth of SEMA7A+ tumors with PI3K inhibitors (GCT-007:10 mg/kg daily, alpelisib: 20mg/kg daily), alone or in combination with tamoxifen (0.5mg/100uL, every 3rd day). Combination of an anti-SEMA7A antibody (SmAbH1) (100-250 ug/100uL, every other day) and fulvestrant (83 mg/kg, every 5 days) also revealed that direct inhibition of SEMA7A via SmAbH1 significantly reduces tumor growth of SEMA7A-expressing tumors, and that the efficacy of SmAbH1 is not diminished by the standard of care, fulvestrant. Overall, our studies suggest that patients with ER+SEMA7A+ tumors should be candidates for PI3K-targeted therapies or anti-SEMA7A-based therapy.

This study reveals that the miR-375-UBE3A-ERα axis contributes to breast cancer progression and tamoxifen resistance. Targeting miR-375 may represent a promising strategy to overcome endocrine resistance in ER+ breast cancer.

The study focuses on the synergistic effect of the obtained 1-substituted isatin-5-sulfonamides, exhibiting pro-apoptotic activity and is combined with heat shock protein 90 (HSP90) and protein kinase B (AKT) selective inhibitors in breast cancer cell lines, which are sensitive and resistant to antiestrogens.To create resistance, 4-hydroxytamoxifen (HT) was applied to create a resistant cell subline (MCF7/HT), achieving a resistance index of 2...Notably,Compound LCTA-3344 did not enhance luciferase activity in the MCF7/p53-LUC cell subline, while chemotherapeutic agent doxorubicin has been determined to be its potent inducer...Compound LCTA-3344 induced apoptosis through a p53-independent mechanism, which holds promise as a novel therapy for hormone-resistant breast cancers. AKT Inhibitor IV caused apoptosis of MCF7 cells to a greater extent than compound LCTA-3344, and their combination resulted in a synergistic effect.

A stepwise, symptom-driven treatment model is recommended-beginning with non-hormonal options and advancing to local vaginal therapies or ospemifene when appropriate...Local estrogen is generally safer in tamoxifen users, but caution is warranted with aromatase inhibitors due to potential systemic absorption. In patients with estrogen receptor-negative disease, local hormone use may be considered but requires careful risk-benefit evaluation and shared decision making is essential. Until long-term safety data emerge, management should remain individualized, evidence-based, and multidisciplinary.

A 41-year-old woman with a history of right-sided invasive ductal carcinoma (IDC) diagnosed in 2022 underwent breast-conserving surgery (BCS) and axillary lymph node dissection (ALND), followed by adjuvant chemotherapy, radiotherapy, and daily tamoxifen (20 mg)...Breast fibromatosis can closely mimic carcinoma both clinically and radiologically, and histologic analysis remains essential for definitive diagnosis. Complete surgical excision with negative margins remains the treatment of choice.

A subset of AI mice were given tamoxifen for 21 days...Early metabolic phenotypes in AI and GI glands may be related to estrogen signaling. AI long-term transcriptional metabolic effects were similar to breast cancer.

Recurrence of breast cancer after mastectomy for DCIS is rare; however, it carries a high mortality rate for those who relapse. Adjuvant tamoxifen after mastectomy demonstrated a significant reduction in the risk of recurrence in ER-positive DCIS. This study supports the decision to prescribe adjuvant ET in patients with DCIS who underwent mastectomy.